-
Pharmaceutical stocks erupt en masse! Subdivisions such as traditional Chinese medicine and medical devices have strengthened
Time of Update: 2022-10-12
The bank believes that with the control of the epidemic, the performance of the pharmaceutical industry in the third quarter is expected to achieve accelerated growth, and in the medium and long term, pay attention to the basic aspects of the post-epidemic period.
-
Express delivery across the blood-brain barrier
Time of Update: 2022-09-07
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamDenali Therapeutics today announced new interim results from a Phase 1/2 clinical trial of its investigational enzyme replacement therapy DNL310 in mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome) .
-
The courier is a blockbuster
Time of Update: 2022-06-05
▎WuXi AppTec Content Team Editor Today, Nkarta announced that the company's two major chimeric antigen receptor (CAR) natural killer (NK) cell candidate therapies, NKX101 and NKX019, are in two early-stage treatments for different blood cancer patient populations.
-
Express delivery requires only one urine sample, and the innovative liquid biopsy is more than 90% accurate in predicting prostate cancer
Time of Update: 2021-10-01
▎The content team editor of WuXi AppTec recently, the data released by miR Scientific at the annual meeting of the American Urological Association (AUA) showed that its technology of using urine to detect prostate cancer can accurately detect prostate cancer at the molecular level and its risks Classification .
-
Courier FDA approves the first drug therapy for fatal pediatric liver disease to avoid liver transplantation and surgery
Time of Update: 2021-08-05
" References: [1] Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC).
Retrieved July 20, 2021, from https:// 2021/07/20/2266030/0/en/Albireo-Announces-FDA-Approval-of-Bylvay-odevixibat-the-First-Drug-Treatment-for-Patients-With-Progressive-Familial-Intrahepatic-Cholestasis-PFIC.
-
Dr Frederick H. hausheer was appointed chief medical officer by Wuxi apptec
Time of Update: 2019-04-08
April 8, 2019 / AP / -- Wuxi apptec today announced that Dr Frederick H hausheer has officially joined the company as chief medical officer Dr hausheer will lead the medical, scientific and operationa
-
[quick news] on May 8, 2018, Changzhou base of Hequan Pharmaceutical Co., Ltd. successfully passed the first site audit of FDA with zero defects
Time of Update: 2018-05-08
The Changzhou base of Hequan Pharmaceutical Co., Ltd has successfully passed the first site audit of FDA in the United States with zero defects Recently, Hequan Pharmaceutical Co., Ltd., a subsidiary
-
Top ten cro enterprises with the most investment value in China in 2014
Time of Update: 2014-12-22
Source: bioprospecting on December 22, 2014, the "2014 China cro industry innovation enterprise top 50 selection" activity organized by PI medicine magazine and Hong and Intelligent Industry Research
